Clinical Study

Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies

Table 1

Baseline demographics of patient subgroups with baseline central retinal thickness < 400 μm or ≥400 μm (integrated data from VIVID-DME and VISTA-DME).

CRT < 400 μmCRT ≥ 400 μm
Laser control ()2q4 ()2q8 ()Laser control ()2q4 ()2q8 ()

Age (y), mean (SD)63.1 (9.2)61.5 (9.2)62.6 (8.2)62.5 (8.5)62.7 (10.4)64.0 (8.8)
Sex (female)36 (46.2)42 (46.7)35 (44.9)87 (41.8)78 (39.0)85 (40.9)
Race
 White69 (88.5)74 (82.2)67 (85.9)168 (80.8)163 (81.5)164 (78.8)
 Other/not reported9 (11.5)16 (17.8)11 (14.1)40 (19.2)37 (18.5)44 (21.2)
HbA1c, mean (SD)7.96 (1.94)8.08 (1.55)7.98 (1.64)7.50 (1.28)7.77 (1.56)7.74 (1.44)
Duration of diabetes (y), mean (SD)17.7 (10.1)17.2 (10.3)15.7 (10.0)15.5 (9.6)14.9 (9.4)16.5 (10.9)
BCVA (letters), mean (SD)63.5 (8.2)63.1 (8.6)63.0 (8.3)59.0 (11.4)58.3 (11.3)57.7 (11.6)
 <40 letters1 (1.3)1 (1.1)1 (1.3)21 (10.1)19 (9.5)23 (11.1)
 ≥40 to <55 letters11 (14.1)19 (21.1)10 (12.8)35 (16.8)38 (19.0)41 (19.7)
 ≥55–65 letters19 (24.4)20 (22.2)30 (38.5)75 (36.1)70 (35.0)72 (34.6)
 ≥65 letters47 (60.3)50 (55.6)37 (47.4)77 (37.0)73 (36.5)72 (34.6)
CRT (μm), mean (SD)338.8 (41.3)343.2 (36.1)337.9 (38.9)568.8 (132.2)555.1 (131.5)551.9 (135.9)
DRSS score
 ≤4329 (37.2)33 (36.7)32 (41.0)79 (38.0)63 (31.5)65 (31.3)
 4719 (24.4)17 (18.9)14 (17.9)31 (14.9)27 (13.5)45 (21.6)
 ≥5330 (38.5)40 (44.4)32 (41.0)98 (47.1)109 (54.5)98 (47.1)
BMI (kg/m2), mean31.4830.0431.7230.0230.9730.02

Values are n (%) unless otherwise noted. 2q4: 2 mg every 4 weeks; 2q8: 2 mg every 8 weeks; BCVA: best-corrected visual acuity; BMI: body mass index; CRT: central retinal thickness; DRSS: diabetic retinopathy severity scale; HbA1c: haemoglobin A1c; SD: standard deviation.